Loading…
MINOCIN MR is a brand name for Minocycline. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: MINOCIN MR Capsules are indicated for the treatment of acne.
Verbatim from this product's MHRA label. Tap a section to expand.
Posology Adults One 100mg capsule every 24 hours Paediatric Population Children over 12 years: One 100mg capsule every 24 hours Children under 12 years: Minocycline is not recommended Elderly No special dosing requirement Method of Administration: To reduce the risk of oesophageal irritation and ulceration, the capsules should be swallowed whole with plenty of fluid, while sitting or standing.
Unlike earlier tetracyclines, absorption of minocycline is not significantly impaired by food or moderate amounts of milk. Treatment of acne should be continued for a minimum of 6 weeks, and where possible limited to a maximum of six months.
If, after six months, there is no satisfactory response Minocin MR should be discontinued and other therapies considered. If Minocin MR is to be continued for longer than six months, patients should be monitored (including laboratory investigations) at least three monthly thereafter for signs and symptoms of hepatitis or systemic lupus erythematosus (SLE) or unusual pigmentation.
(see Special Warnings and Precautions)
). Minocin MR should be used with caution in patients with hepatic dysfunction and in conjunction with alcohol and other hepatotoxic drugs. It is recommended that alcohol consumption should remain within the Government’s recommended limits.
Rare cases of auto-immune hepatotoxicity and isolated cases of systemic lupus erythematosus (SLE) and also exacerbation of pre-existing SLE have been reported. If patients develop signs or symptoms of SLE or hepatotoxicity, or suffer exacerbation of pre-existing SLE, minocycline should be discontinued.
Other rare, serious events have occurred with Minocin MR including Stevens- Johnson Syndrome and toxic epidermal necrolysis. 8 Undesirable effects). Minocin MR should be discontinued if either of these serious skin reactions is suspected.
Clinical studies have shown that there is no significant drug accumulation in patients with renal impairment when they are treated with Minocin MR in the recommended doses. In cases of severe renal insufficiency, reduction of dosage and monitoring of renal function may be required.
The anti-anabolic action of the tetracyclines may cause an increase in serum urea. In patients with significantly impaired renal function, higher serum levels of tetracyclines may lead to uraemia, hyperphosphataemia and acidosis. If renal impairment exists, even usual oral and parenteral doses may lead to excessive systemic accumulations of the drug and possible liver toxicity.
Caution is advised in patients with myasthenia gravis as tetracyclines can cause weak neuromuscular blockade. Cross-resistance between tetracyclines may develop in micro-organisms and cross-sensitisation in patients. g. enteritis, glossitis, stomatitis, vaginitis, pruritus ani or Staphylococcal enteritis.
Patients taking oral contraceptives should be warned that if diarrhoea or breakthrough bleeding occur there is a possibility of contraceptive failure. 8 Undesirable Effects). Hyperpigmentation may present regardless of dose or duration of therapy but develops more commonly during long term treatment.
8 Undesirable effects). Minocin MR should be used with caution in patients with hepatic dysfunction and in conjunction with alcohol and other hepatotoxic drugs. It is recommended that alcohol consumption should remain within the Government’s recommended limits.
Rare cases of auto-immune hepatotoxicity and isolated cases of systemic lupus erythematosus (SLE) and also exacerbation of pre-existing SLE have been reported. If patients develop signs or symptoms of SLE or hepatotoxicity, or suffer exacerbation of pre-existing SLE, minocycline should be discontinued.
Other rare, serious events have occurred with Minocin MR including Stevens- Johnson Syndrome and toxic epidermal necrolysis. 8 Undesirable effects). Minocin MR should be discontinued if either of these serious skin reactions is suspected.
Clinical studies have shown that there is no significant drug accumulation in patients with renal impairment when they are treated with Minocin MR in the recommended doses. In cases of severe renal insufficiency, reduction of dosage and monitoring of renal function may be required.
The anti-anabolic action of the tetracyclines may cause an increase in serum urea. In patients with significantly impaired renal function, higher serum levels of tetracyclines may lead to uraemia, hyperphosphataemia and acidosis. If renal impairment exists, even usual oral and parenteral doses may lead to excessive systemic accumulations of the drug and possible liver toxicity.
Caution is advised in patients with myasthenia gravis as tetracyclines can cause weak neuromuscular blockade. Cross-resistance between tetracyclines may develop in micro-organisms and cross-sensitisation in patients. g. enteritis, glossitis, stomatitis, vaginitis, pruritus ani or Staphylococcal enteritis.
Patients taking oral contraceptives should be warned that if diarrhoea or breakthrough bleeding occur there is a possibility of contraceptive failure. 8 Undesirable Effects). Hyperpigmentation may present regardless of dose or duration of therapy but develops more commonly during long term treatment.
Use of minocycline is contraindicated in the following: • Hypersensitivity to the active substance minocycline, other tetracyclines or to any of the excipients. • Pregnancy and lactation. • Children under the age of 12 years. • Complete renal failure.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Minocycline in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Patients should be advised to report any unusual pigmentation without delay and Minocin MR should be discontinued. If a photosensitivity reaction occurs, patients should be warned to avoid direct exposure to natural or artificial light and to discontinue therapy at the first signs of skin discomfort.
As with other tetracyclines, bulging fontanelleles in infants and benign intracranial hypertension in juveniles and adults have been reported. Presenting features were headache and visual disturbances including blurring of vision, scotoma and diplopia.
Permanent vision loss has been reported. Treatment should cease if evidence of raised intracranial pressure develops.
Elderly:
Dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Paediatric population:
The use of tetracyclines during tooth development in children under the age of 12 years may cause permanent discolouration. Enamel hypoplasia has also been reported.
Laboratory monitoring:
Periodic laboratory evaluations of organ system function, including haematopoietic, renal and hepatic should be conducted. 5 Interaction with other medicinal products and other forms of interaction Tetracyclines depress plasma prothrombin activity and reduced doses of concomitant anticoagulants may be necessary.
Diuretics may aggravate nephrotoxicity by volume depletion. Bacteriostatic drugs may interfere with the bactericidal action of penicillin. Avoid giving tetracycline-class drugs in conjunction with penicillin. Absorption of Minocin MR is impaired by the concomitant administration of antacids, iron, calcium, magnesium, aluminium bismuth and zinc salts (interactions with specific salts, antacids, bismuth containing ulcer – healing drugs, quinapril which contains a magnesium carbonate excipient).
It is recommended that any indigestion remedies, vitamins, or other supplements containing these salts are taken at least 3 hours before or after a dose of Minocin MR. Unlike earlier tetracyclines, absorption of Minocin MR is not significantly impaired by food or moderate amounts of milk.
The concomitant use of tetracyclines may reduce the efficacy of oral contraceptives. Administration of isotretinoin should be avoided shortly before, during and shortly after minocycline therapy. 4 Special warnings and precautions).
Interference with laboratory and other diagnostic tests:
False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test. 6 Fertility, Pregnancy and lactation Use in pregnancy: Minocycline is contraindicated during pregnancy as it can cause fetal harm.
Results of animal studies indicate that tetracyclines cross the placenta, are found in foetal tissues and can have toxic effects on the developing foetus (often related to retardation of skeletal development). Evidence of embryotoxicity has also been noted in animals treated early in pregnancy.
Minocin MR therefore, should not be used in pregnancy unless considered essential. In humans, minocycline like other tetracycline-class antibiotics, crosses the placenta and may cause foetal harm when administered to a pregnant woman.
In addition, there have been post marketing reports of congenital abnormalities including limb reduction. If Minocin MR is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be informed of the potential hazard to the foetus.
The use of drugs of the tetracycline class during tooth development (last half of pregnancy) may cause […]
Patients should be advised to report any unusual pigmentation without delay and Minocin MR should be discontinued. If a photosensitivity reaction occurs, patients should be warned to avoid direct exposure to natural or artificial light and to discontinue therapy at the first signs of skin discomfort.
As with other tetracyclines, bulging fontanelleles in infants and benign intracranial hypertension in juveniles and adults have been reported. Presenting features were headache and visual disturbances including blurring of vision, scotoma and diplopia.
Permanent vision loss has been reported. Treatment should cease if evidence of raised intracranial pressure develops.
Elderly:
Dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Paediatric population:
The use of tetracyclines during tooth development in children under the age of 12 years may cause permanent discolouration. Enamel hypoplasia has also been reported.
Laboratory monitoring:
Periodic laboratory evaluations of organ system function, including haematopoietic, renal and hepatic should be conducted.